The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I dose-escalation study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma and other solid tumors.
 
Bixia Tang
No Relationships to Disclose
 
Zhihong Chi
No Relationships to Disclose
 
Rong Duan
No Relationships to Disclose
 
Lu Si
Honoraria - MSD; Novartis; Oriengene; Roche China; Shanghai Junshi Biosciences
 
Chuanliang Cui
No Relationships to Disclose
 
Xinan Sheng
Speakers' Bureau - BeiGene; Junshi Pharmaceuticals; Novartis; Pfizer; RemeGen
 
Xieqiao Yan
No Relationships to Disclose
 
Lili Mao
Honoraria - MSD; Novartis; Shanghai Junshi BioSciences
Research Funding - MSD
 
BIN LIAN
No Relationships to Disclose
 
Xuan Wang
Consulting or Advisory Role - Oriengene
 
Siming Li
No Relationships to Disclose
 
Li Zhou
No Relationships to Disclose
 
Xue Bai
Other Relationship - Bristol-Myers Squibb
 
Xiaoting Wei
No Relationships to Disclose
 
Luyin Ding
Employment - Harbour BioMed
Stock and Other Ownership Interests - Harbour BioMed
Honoraria - Harbour BioMed
 
Xuan Chen
Employment - Harbour BioMed
 
Xiaoxiang Chen
Employment - Harbour BioMed
Leadership - Harbour BioMed
Stock and Other Ownership Interests - Harbour BioMed
Research Funding - Harbour BioMed
Travel, Accommodations, Expenses - Harbour BioMed
Other Relationship - Harbour BioMed
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere